Anti-Hypertensive Drugs - Bhutan

Bhutan

The projected revenue for the Anti-Hypertensive Drugs market in Bhutan is expected to reach US$125.90k in the year 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of -0.27%, leading to a market volume of US$124.20k by the year 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue, with an estimated amount of US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Bhutan is steadily increasing due to the country's rising prevalence of hypertension and growing awareness about the importance of managing high blood pressure.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Bhutan has been on the rise in recent years.

Customer preferences: Bhutanese consumers are becoming increasingly health-conscious and are prioritizing preventative measures to avoid chronic illnesses such as hypertension. As a result, there has been a growing demand for Anti-Hypertensive Drugs in the country.

Trends in the market: The Anti-Hypertensive Drugs market in Bhutan has been growing steadily due to the increasing prevalence of hypertension in the country. The market is dominated by a few major players, but there has been an influx of new entrants in recent years. These new players are introducing innovative products with improved efficacy and fewer side effects, which is driving competition in the market.

Local special circumstances: Bhutan is a small country with a population of just over 750,000 people. The country has a unique culture and is known for its focus on Gross National Happiness (GNH) rather than Gross Domestic Product (GDP). This focus on happiness and well-being has led to a greater emphasis on preventative healthcare measures, which is driving demand for Anti-Hypertensive Drugs in the country.

Underlying macroeconomic factors: Bhutan is a developing country with a small economy that is heavily dependent on hydropower exports. The country has been investing heavily in healthcare infrastructure and has made significant progress in improving access to healthcare services in recent years. This investment in healthcare, combined with the growing demand for Anti-Hypertensive Drugs, is expected to drive growth in the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.